• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 20-F/A filed by Genenta Science S.p.A. (Amendment)

    4/1/24 5:28:59 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email
    true FY 0001838716 0001838716 2023-01-01 2023-12-31 0001838716 dei:BusinessContactMember 2023-01-01 2023-12-31 0001838716 GNTA:AmericanDepositarySharesEachAmericanDepositaryShareRepresentingOneOrdinaryShareMember 2023-01-01 2023-12-31 0001838716 GNTA:OrdinarySharesNoParValueMember 2023-01-01 2023-12-31 0001838716 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 20-F/A

    (Amendment No. 1)

     

    (Mark One)

     

    ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12 (g) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the fiscal year ended December 31, 2023

     

    OR

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    OR

     

    ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of event requiring this shell company report__________

     

    For the transition period from __________ to __________

     

    Commission file number: 001-41115

     

    Genenta Science S.p.A.

    (Exact name of Registrant as specified in its charter)

     

    N/A

    (Translation of Registrant’s name into English)

     

    Italy

    (Jurisdiction of incorporation or organization)

     

    Via Olgettina No. 58

    20132 Milan, Italy

    (Address of principal executive offices)

     

    Via Olgettina No. 58

    20132 Milan, Italy

    Attn: Pierluigi Paracchi

    Tel: +39-02-2643-4681

    Email: [email protected]

    (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    American depositary shares (each American depositary share representing one ordinary share)   GNTA  

    The Nasdaq Stock Market LLC

    (The Nasdaq Capital Market)

             
    Ordinary shares, no par value*      

    The Nasdaq Stock Market LLC

    (The Nasdaq Capital Market)

     

     

    * Not for trading, but only in connection with the listing of American depositary shares on The Nasdaq Capital Market.

     

    Securities registered or to be registered pursuant to Section 12(g) of the Act:

     

    None

    (Title of Class)

     

    Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

     

    None

    (Title of Class)

     

    Indicate the number of outstanding shares of each of the Issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

     

    The registrant had 18,216,958 ordinary shares outstanding as of December 31, 2023.

     

    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

     

    If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. ☐ Yes ☒ No

     

    Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

     

    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

    ☒ Yes ☐ No

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Emerging growth company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

     

    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

     

    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

     

    Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

     

    U.S. GAAP ☒   International Financial Reporting Standards as issued by the International Accounting Standards Board ☐   Other ☐

     

    If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. ☐ Item 17 ☐ Item 18

     

    If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

     

    (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

     

    Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No

     

    Auditor Name Auditor Firm ID Auditor Location
    Dannible & McKee, LLP 528 Syracuse, New York

     

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    On March 29, 2024, Genenta Science S.p.A. (the “Company”) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023 (the “Original Filing”). This Amendment No. 1 (the “Amendment”) amends the Original Filing solely to file the consent of the Company’s independent registered public accounting firm, Dannible & McKee, LLP (the “Auditor Consent”), which was inadvertently omitted in the Original Filing.

     

    This Amendment is being filed solely to file the Auditor Consent. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the date of the Original Filing or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant’s other filings with the Securities and Exchange Commission.

     

    In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d- 14(a) of the Exchange Act.

     

     
     

     

    ITEM 19. EXHIBITS

     

    Exhibit No.   Description
    12.1   Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended
    12.2   Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act, as amended
    13.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
    23.1   Consent of Dannible & McKee. LLP
    101.INS   Inline XBRL Instance Document
    101.SCH   Inline XBRL Taxonomy Extension Schema Document
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

     

     
     

     

    SIGNATURES

     

    The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

     

    GENENTA SCIENCE S.P.A.

     

    By: /s/ Pierluigi Paracchi   By: /s/ Richard B. Slansky
    Name: Pierluigi Paracchi   Name: Richard B. Slansky
    Title: Chief Executive Officer (Principal Executive Officer)   Title: Chief Financial Officer (Principal Financial and Accounting Officer)
    Date: April 1, 2024   Date: April 1, 2024

     

     

     

    Get the next $GNTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    SEC Filings

    View All

    SEC Form 424B5 filed by Genenta Science S.p.A.

    424B5 - Genenta Science S.p.A. (0001838716) (Filer)

    1/27/26 6:10:58 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    1/27/26 6:05:38 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    1/27/26 6:03:51 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

    Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial IntegrationPraexidia Foundation Joins as a Long-Term Strategic ShareholderCorporate Name Change to Saentra Forge S.p.A.Biotech Clinical Updates and Partnering StrategyCash, Cash Equivalents, and Marketable Securities of approx. $33 million MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A (NASDAQ:GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industr

    1/27/26 3:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Science Provides Update on CEO Ownership

    MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi. Over time, Mr. Paracchi has acquired 30,000 American Depositary Shares ("ADSs") of the Company in total through open-market purchases. As reported in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), Mr. Paracchi's transactions in the Company's securities have consisted of open-market purchases, with no reported sales. As calculated in accordance

    12/19/25 2:30:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

    MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients have been treated with Temferon. These data1 are compared to the previously disclosed April 15, 2025 cut, communicated on July 1, 2025. More than seven months after the prior update, key survival metrics for the TEM-GBM patients remain consistent. 44% of pati

    11/24/25 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

    ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

    6/29/23 9:11:48 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

    H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

    7/25/22 7:15:53 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Leadership Updates

    Live Leadership Updates

    View All

    ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

    Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

    1/8/25 3:17:00 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

    MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

    5/6/24 6:25:00 AM ET
    $ARYD
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

    Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

    1/17/23 8:00:00 AM ET
    $AGRX
    $GNTA
    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Package Goods/Cosmetics

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/12/24 4:05:34 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/10/23 6:02:50 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Genenta Science S.p.A.

    SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

    2/25/22 1:17:49 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care